HAYWARD, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced that a Late Breaking Abstract on BB-301 was accepted for oral presentation at the […]
Category Archives: Pr Newswire
Pr Newswire
BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference
18
Sep
Sep
GAITHERSBURG, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces the Company will present further data from BiomX’s Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas […]
SHENZHEN, China , Sept. 18, 2024 /PRNewswire/ — TerraMaster, a leading brand in home and enterprise storage solutions, has recently announced the launch of 9 new NAS models, all equipped with its latest TOS 6 operating system. This lineup includes two 8-bay all-flash NAS models specifically designed for high-performance needs. All new products were officially launched […]
LONDON, Sept. 18, 2024 /PRNewswire/ — Polus Capital Management (“Polus”), a leading investment management firm specialising in alternative credit strategies, today announces that it has secured a capital commitment for its Special Situations strategy from a wholly owned subsidiary of Abu Dhabi Investment Authority (ADIA). Following the commitment, Polus’ Special Situations strategy has approximately $5 […]
Moomoo Singapore received the prestigious award at the SIAS Investors’ Choice Awards Recognises Moomoo Singapore’s commitment to democratise investing for all Holds added significance for Moomoo Singapore as we hit more than 1 million users SINGAPORE, Sept. 18, 2024 /PRNewswire/ — Moomoo Financial Singapore Pte. Ltd. (“Moomoo Singapore”) has been named the Best Retail Broker in […]
BARCELONA, Spain, Sept. 18, 2024 /PRNewswire/ — The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading cancer experts and researchers from around the globe, showcasing the latest advancements in the field […]
80% of Global Commercial Fleet Leaders Surveyed Set Goal for 25% EVs by 2030, Latest Frost & Sullivan Insights Reveal LONDON, Sept. 18, 2024 /PRNewswire/ — Conducted by Frost & Sullivan and commissioned by WEX (NYSE: WEX), a new report provides key insights for organisations managing mixed-energy fleets across Europe, North America, and Asia-Pacific. The […]
18
Sep
Sep
HALIFAX, Nova Scotia, Sept. 17, 2024 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced the results from its annual and special meeting of shareholders held earlier today. Based on the proxies received and the […]
18
Sep
Sep
Hamilton, Bermuda, Sept. 17, 2024 (GLOBE NEWSWIRE) — $4 million upfront with up to an additional $8 million of aggregate gross proceeds upon the exercise in full for cash of milestone-linked warrants Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq: CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the […]
Pr Newswire
Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025
18
Sep
Sep
MONTREAL, Sept. 17, 2024 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced a risk of a temporary supply disruption for EGRIFTA SV® (tesamorelin for injection) in early 2025 caused by an unexpected voluntary shutdown of the […]